Back to News
Market Impact: 0.3
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Source: globenewswire.com
Healthcare & BiotechCompany Fundamentals
Regeneron expanded its 2020 procurement agreement with BARDA for its first-in-class antibody treatment for Orthoebolavirus zairense, adding approximately $270 million in value.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
REGN0.70
More News
- Regeneron extends Ebola treatment supply deal with US government
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation